Penbutolol
beta-Adrenergic Blocker — CARDIOVASCULAR SYSTEM
Also known as: betapressin, levopenbutolol, penbutolol sulfate
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Penbutolol is an ofm drug in the beta-Adrenergic Blocker class catalogued in DrugCentral. It was first approved by the FDA in 1987. Its mechanism of action is classified as Adrenergic beta-Antagonists. DrugCentral lists 5 molecular targets, including ADRB2, ADRB1 and Htr1a. Recorded indications include Hypertensive disorder.
- Approval status: ofm (first approved 1987 by the FDA).
- Drug class: beta-Adrenergic Blocker.
- Mechanism of action: Adrenergic beta-Antagonists.
- Molecular targets: ADRB2, ADRB1, Htr1a and HTR1A (5 listed in DrugCentral).
- Indications: Hypertensive disorder.
- ATC code: C07AA23 (Beta blocking agents, non-selective).
- Molecular formula: C18H29NO2; molecular weight 291.44 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Hypertensive disorder
Off-label uses (1)
- Angina pectoris
Contraindications (17)
- Anaphylaxis
- Bronchospasm
- Cardiogenic shock
- Complete atrioventricular block
- Decompensated cardiac failure
- Depressive disorder
- Diabetes mellitus
- Disease of liver
- Kidney disease
- Myasthenia gravis
- Partial atrioventricular block
- Pregnancy, function
- Pulmonary emphysema
- Raynaud's phenomenon
- Right ventricular failure
- Severe chronic obstructive pulmonary disease
- Sinus bradycardia
Mechanism & targets
| Mechanism of action (MoA) | Adrenergic beta-Antagonists |
|---|---|
| Established pharmacologic class | beta-Adrenergic Blocker |
Molecular targets (5)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Beta-2 adrenergic receptor | ADRB2 | antagonist | Ki 9.00 |
| Beta-1 adrenergic receptor | ADRB1 | antagonist | Ki 8.80 |
| 5-hydroxytryptamine receptor 1A | Htr1a | unknown | Ki 8.62 |
| 5-hydroxytryptamine receptor 1A | HTR1A | unknown | Ki 7.92 |
| Alpha-1-acid glycoprotein 1 | ORM1 | unknown | — |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1987-12-30 | FDA | — | — |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
C07AA23 | CARDIOVASCULAR SYSTEM › BETA BLOCKING AGENTS › BETA BLOCKING AGENTS › Beta blocking agents, non-selective |
C07CA23 | CARDIOVASCULAR SYSTEM › BETA BLOCKING AGENTS › BETA BLOCKING AGENTS AND OTHER DIURETICS › Beta blocking agents, non-selective, and other diuretics |
Chemical structure
| Molecular formula | C18H29NO2 |
|---|---|
| Molecular weight | 291.44 g/mol |
| CAS number | 38363-40-5 |
| InChIKey | KQXKVJAGOJTNJS-HNNXBMFYSA-N |
| PubChem CID | 37464 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Penbutolol used for?
DrugCentral lists the following indications for Penbutolol: Hypertensive disorder.
How does Penbutolol work?
Penbutolol is classified as Adrenergic beta-Antagonists; its molecular targets in DrugCentral include ADRB2 (antagonist), ADRB1 (antagonist), Htr1a and HTR1A.
When was Penbutolol first approved?
Penbutolol was first approved by the FDA in 1987.
What drug class does Penbutolol belong to?
Penbutolol is in the beta-Adrenergic Blocker class.
What is the chemical formula of Penbutolol?
Penbutolol has the molecular formula C18H29NO2 and a molecular weight of 291.44 g/mol.
Browse: all drugs starting with P · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 2078 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1290 — compound record and bioactivity
- PubChem CID 37464 — chemical identifiers
- DrugBank DB01359 — drug record
- FDA UNII 78W62V43DY — substance identity
- DailyMed: FDA labels for Penbutolol — current prescribing information (label search)
- UniProt P07550 (ADRB2) — target protein
- UniProt P08588 (ADRB1) — target protein
- UniProt P08908 (HTR1A) — target protein
- UniProt P02763 (ORM1) — target protein
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.